Callan Family Office LLC Invests $655,000 in Genmab A/S Sponsored ADR $GMAB

Callan Family Office LLC purchased a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,681 shares of the company’s stock, valued at approximately $655,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its stake in Genmab A/S by 3.2% during the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after buying an additional 532 shares during the last quarter. Park Avenue Securities LLC raised its holdings in shares of Genmab A/S by 5.9% in the 2nd quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock valued at $309,000 after buying an additional 832 shares during the period. Gallacher Capital Management LLC raised its holdings in shares of Genmab A/S by 6.8% in the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company’s stock valued at $281,000 after buying an additional 915 shares during the period. Eagle Global Advisors LLC raised its holdings in shares of Genmab A/S by 0.5% in the 2nd quarter. Eagle Global Advisors LLC now owns 210,295 shares of the company’s stock valued at $4,345,000 after buying an additional 1,000 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on GMAB. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Truist Financial upped their target price on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. Wall Street Zen upgraded Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. HC Wainwright raised their price target on Genmab A/S from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Finally, Zacks Research upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.80.

Genmab A/S Price Performance

GMAB opened at $32.68 on Tuesday. The business has a 50 day simple moving average of $27.07 and a 200-day simple moving average of $23.00. The stock has a market capitalization of $20.98 billion, a P/E ratio of 16.42, a P/E/G ratio of 1.79 and a beta of 0.98. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $33.63.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.